Table 1.
Baseline Characteristics
| Characteristics | Clidinium/Chlordiazepoxide (n = 39) | Placebo (n = 39) | P-values |
|---|---|---|---|
| Age (year) | 43 (36.5-60.5) | 50 (39-59) | 0.204 |
| Female | 25 (75.8) | 21 (67.7) | 0.664 |
| BMI (kg/m2) | 21.3 (19.6-24.5) | 22.6 (20.4-25.2) | 0.188 |
| Underlying disease | 15 (45.5) | 11 (35.5) | 0.578 |
| Hypertension | 8 (53.3) | 6 (54.5) | 0.865 |
| Other | 7 (46.7) | 5 (45.5) | |
| Smoker | 1 (3.0) | 3 (9.7) | 0.347 |
| Alcohol drinker | 4 (12.1) | 0 (0.0) | 0.114 |
| Duration of symptom (months) | 16 (10-24) | 12 (12-36) | 0.608 |
| FD Subtype | 0.399 | ||
| PDS | 9 (27.3) | 12 (38.7) | |
| EPS | 11 (33.3) | 6 (19.4) | |
| Mixed type | 13 (39.4) | 13 (41.9) | |
| GOSS | 32.6 ± 7.2 | 31.2 ± 8.1 | 0.427 |
| Short form NPI | 30.1 ± 5.9 | 26.8 ± 6.6 | 0.026 |
BMI, body mass index; FD, functional dyspepsia; PDS, postprandial distress syndrome; EPS, epigastrium pain syndrome; GOSS, global overall symptom scale; NPI, Nepean dyspepsia index.
Data are presented as median (interquartile range), number (%), or mean ± SD.